Foghorn Therapeutics

OverviewSuggest Edit

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. Through its Gene Traffic Control platform, the company studies, identifies, and validates potential drug targets within the chromatin regulatory system.

TypePublic
Founded2016
HQCambridge, US
Websitefoghorntx.com

Latest Updates

Employees (est.) (Aug 2020)85
Share Price (Nov 2020)$16.9 (-2%)
Cybersecurity ratingAMore

Key People/Management at Foghorn Therapeutics

Adrian Gottschalk

Adrian Gottschalk

President & CEO
Samuel Agresta

Samuel Agresta

Chief Medical Officer
Fanny Cavalié

Fanny Cavalié

SVP, Business & Operations
Steve Bellon

Steve Bellon

SVP, Drug Discovery
Carlos Costa

Carlos Costa

SVP, People & Organization
Carl P. Decicco

Carl P. Decicco

Chief Scientific Officer
Show more

Foghorn Therapeutics Office Locations

Foghorn Therapeutics has an office in Cambridge
Cambridge, US (HQ)
NE47, 500 Technology Square #700
Show all (1)

Foghorn Therapeutics Financials and Metrics

Foghorn Therapeutics Revenue

USD

Net income (H1, 2020)

(29.7m)

EBIT (H1, 2020)

(29.3m)

Market capitalization (20-Nov-2020)

622.2m

Closing stock price (20-Nov-2020)

16.9

Cash (30-Jun-2020)

36.6m

EV

636.1m
Foghorn Therapeutics's current market capitalization is $622.2 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

4.8m6.7m

R&D expense

21.2m44.4m

Operating expense total

26.0m51.1m

EBIT

(26.0m)(51.1m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

3.2m4.1m

R&D expense

19.6m25.1m

Operating expense total

22.8m29.3m

EBIT

(22.8m)(29.3m)
Annual
USDFY, 2018FY, 2019

Cash

40.0m15.0m

Current Assets

40.4m16.9m

PP&E

2.1m2.7m

Total Assets

43.1m22.3m
Quarterly
USDQ2, 2020

Cash

36.6m

Current Assets

39.0m

PP&E

8.2m

Total Assets

94.3m
Annual
USDFY, 2018FY, 2019

Net Income

(26.3m)(51.1m)

Depreciation and Amortization

379.0k693.0k

Accounts Payable

1.3m1.2m

Cash From Operating Activities

(22.6m)(46.3m)
Quarterly
USDQ2, 2019Q2, 2020

Net Income

(22.7m)(29.7m)

Depreciation and Amortization

290.0k509.0k

Accounts Payable

1.1m(285.0k)

Cash From Operating Activities

(20.9m)(23.4m)
USDFY, 2018

Financial Leverage

-1.1 x
Show all financial metrics

Foghorn Therapeutics Operating Metrics

Q2, 2020

Discovery Stage Products

3

IND-Enabling Stage Products

2
Show all operating metrics

Foghorn Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Foghorn Securities Corporation

Foghorn Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Foghorn Therapeutics Online and Social Media Presence

Embed Graph

Foghorn Therapeutics News and Updates

Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Mich…

Foghorn Therapeutics sets IPO terms, to raise up to $127.5 million

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to raise up to $127.5 million. The company is offering 7.5 million shares in the IPO, which is expected to pr…

Foghorn Therapeutics Blogs

Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

The post Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target appeared first on Foghorn Therapeutics.

Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors

New Director to Bring 30+ Years of Drug Development Expertise as Foghorn Prepares to Enter the Clinic The post Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors appeared first on Foghorn Therapeutics.

Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments

Samuel Agresta appointed Chief Medical Officer; Allan Reine to serve as Chief Financial Officer The post Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments appeared first on Foghorn Therapeutics.

Foghorn Therapeutics Frequently Asked Questions

  • When was Foghorn Therapeutics founded?

    Foghorn Therapeutics was founded in 2016.

  • Who are Foghorn Therapeutics key executives?

    Foghorn Therapeutics's key executives are Adrian Gottschalk, Samuel Agresta and Fanny Cavalié.

  • How many employees does Foghorn Therapeutics have?

    Foghorn Therapeutics has 85 employees.

  • Who are Foghorn Therapeutics competitors?

    Competitors of Foghorn Therapeutics include Nurix, Kymera Therapeutics and Arvinas.

  • Where is Foghorn Therapeutics headquarters?

    Foghorn Therapeutics headquarters is located at NE47, 500 Technology Square #700, Cambridge.

  • Where are Foghorn Therapeutics offices?

    Foghorn Therapeutics has an office in Cambridge.

  • How many offices does Foghorn Therapeutics have?

    Foghorn Therapeutics has 1 office.